Zacks Research Weighs in on Glaukos’ Q2 Earnings (NYSE:GKOS)

Glaukos Corporation (NYSE:GKOS) – Equities researchers at Zacks Research reduced their Q2 2026 EPS estimates for shares of Glaukos in a research note issued on Wednesday, May 20th. Zacks Research analyst Team now forecasts that the medical instruments supplier will earn ($0.29) per share for the quarter, down from their prior forecast of ($0.24). The consensus estimate for Glaukos’ current full-year earnings is ($0.57) per share. Zacks Research also issued estimates for Glaukos’ Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.02) EPS, FY2026 earnings at ($0.65) EPS and Q1 2027 earnings at ($0.07) EPS.

Several other brokerages have also recently commented on GKOS. BTIG Research boosted their target price on Glaukos from $141.00 to $162.00 and gave the stock a “buy” rating in a report on Thursday. Citigroup lifted their price target on Glaukos from $135.00 to $140.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Wells Fargo & Company boosted their price objective on Glaukos from $135.00 to $138.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. JPMorgan Chase & Co. upped their price objective on Glaukos from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Glaukos presently has a consensus rating of “Moderate Buy” and a consensus price target of $146.17.

Glaukos Trading Down 3.4%

Glaukos stock opened at $139.00 on Friday. Glaukos has a 12-month low of $73.16 and a 12-month high of $148.11. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.43 and a quick ratio of 4.73. The stock has a market capitalization of $8.16 billion, a PE ratio of -42.38 and a beta of 0.94. The firm has a 50 day simple moving average of $119.83 and a 200-day simple moving average of $113.29.

Glaukos (NYSE:GKOS) last released its earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.12. Glaukos had a negative net margin of 34.34% and a negative return on equity of 6.92%. The firm had revenue of $150.57 million for the quarter, compared to analysts’ expectations of $137.00 million. During the same quarter last year, the company earned ($0.22) EPS. Glaukos’s quarterly revenue was up 41.2% on a year-over-year basis.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC raised its holdings in shares of Glaukos by 2.6% during the first quarter. AQR Capital Management LLC now owns 7,788 shares of the medical instruments supplier’s stock valued at $766,000 after acquiring an additional 198 shares during the period. Jones Financial Companies Lllp grew its position in Glaukos by 1,405.9% during the 1st quarter. Jones Financial Companies Lllp now owns 2,560 shares of the medical instruments supplier’s stock worth $252,000 after purchasing an additional 2,390 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Glaukos by 41.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 229,994 shares of the medical instruments supplier’s stock valued at $22,636,000 after purchasing an additional 67,668 shares during the period. M&T Bank Corp acquired a new stake in Glaukos during the 2nd quarter valued at $203,000. Finally, Gamco Investors INC. ET AL lifted its holdings in shares of Glaukos by 10.7% in the second quarter. Gamco Investors INC. ET AL now owns 8,001 shares of the medical instruments supplier’s stock valued at $826,000 after purchasing an additional 773 shares in the last quarter. 99.04% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, COO Joseph E. Gilliam sold 19,573 shares of the stock in a transaction on Friday, May 1st. The stock was sold at an average price of $143.54, for a total transaction of $2,809,508.42. Following the completion of the sale, the chief operating officer owned 73,419 shares in the company, valued at approximately $10,538,563.26. This represents a 21.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gilbert H. Kliman sold 5,000 shares of the firm’s stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $140.76, for a total value of $703,800.00. Following the sale, the director directly owned 35,528 shares of the company’s stock, valued at approximately $5,000,921.28. This represents a 12.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 45,930 shares of company stock worth $6,321,363 over the last three months. Corporate insiders own 5.90% of the company’s stock.

Key Glaukos News

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Zacks Research raised its Q1 2027 EPS estimate to a smaller loss of $(0.07) from $(0.10), suggesting slightly better-than-expected longer-term momentum. Glaukos Research Page
• Positive Sentiment: The firm also improved its FY2026 loss estimate to $(0.65) per share from $(0.67), indicating a small improvement in expected full-year profitability. Glaukos Research Page
• Neutral Sentiment: Zacks lifted its FY2028 EPS estimate to $1.56 from $1.68, a revision that points to slightly lower long-term expectations, though the outlook remains profitable. Glaukos Research Page
• Negative Sentiment: Near-term estimates were cut for Q2 2026 to $(0.29) from $(0.24) and for Q3 2026 to $(0.16) from $(0.15), reflecting softer expected earnings in the coming quarters. Glaukos Research Page
• Negative Sentiment: Q4 2026 EPS was also nudged down to $(0.02) from $(0.01), while FY2027 estimates were reduced to $0.38 from $0.42, which may weigh on sentiment around the stock’s forward earnings trajectory. Glaukos Research Page

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.